An observational study in Pulmonary Arterial Hypertension, sponsored by Sentara Norfolk General Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 1 Day and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Sentara Norfolk General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 313 studies in Pulmonary Arterial Hypertension with a site in United States — 39 open to participants now, 57 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.
Among the 313 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 17th largest by planned enrollment of the 60 observational ones that give a count, is the only one that started in 2027, is one of 60 observational ones, reaches primary completion later than 53 of the 56 other live ones, and was the 313th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →39 of the 313 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
35Pharma Inc., a GSK company · Sites in United States, Spain, United Kingdom
Ages 18+
Insmed Incorporated · Sites in United States, Argentina, Australia and 5 more countries
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 1 Day and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
313 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 94 · Phase 3 73 · Phase 4 33
First in 2002; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 650 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 40 across the 253 interventional studies, 73 across the 60 observational. Of the 235 that completed or were terminated, 133 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
186 of 313 have an industry lead sponsor. The 10 most frequent:
Sentara Norfolk General Hospital is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Sentara Norfolk General Hospital has 1 study filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
18 of the studies in Pulmonary Arterial Hypertension with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06274801Phase 3Gossamer Bio USA, Inc.Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | 2026-12 |
| NCT05649748Phase 3Insmed IncorporatedAn Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | 2026-12-31 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT07312227Massachusetts General HospitalA Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 313 studies in Pulmonary Arterial Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pulmonary arterial hypertension (PAH) is a rare and progressive disease associated with significant illness and reduced survival. The PHORA-USE Registry (PHORAR) is a prospective, multicenter observational registry designed to collect real-world clinical data from adult and pediatric patients with PAH receiving routine clinical care. The purpose of this registry is to create a centralized database that can be used to better understand patient characteristics, treatment patterns, disease progression, and clinical outcomes. Information collected through the registry will support observational analyses aimed at identifying factors associated with outcomes and may contribute to the development of improved risk assessment and treatment strategies for patients with PAH.
Adult and pediatric patients with pulmonary arterial hypertension (PAH) receiving care at participating pulmonary hypertension centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult and pediatric patients with pulmonary arterial hypertension (PAH) enrolled in the PHORA-USE Registry (PHORAR). Participants will receive routine clinical care as determined by their treating clinicians. Clinical data will be collected from existing medical records and standard-of-care documentation and followed longitudinally for observational analyses of patient characteristics, treatment patterns, disease progression, and outcomes.
Other: Routine Clinical Care
Participants receive routine clinical care for pulmonary arterial hypertension as determined by their treating clinicians. No drugs, devices, procedures, diagnostic tests, or clinical interventions are assigned by the study protocol. The only research activity is abstraction of data from existing medical records for inclusion in the registry.
Overall survival among participants with pulmonary arterial hypertension
Assessment of overall survival among adult and pediatric participants with pulmonary arterial hypertension enrolled in the PHORA-USE Registry
Time frame: Up to 4 years
Number of participants who underwent organ transplantation (lung, heart-lung, heart, lung-liver, or lung-kidney)
Occurrence of transplantation as documented in the electronic health record. Transplant type is recorded as one of: lung transplant, heart-lung transplant, heart transplant, lung-liver transplant, or lung-kidney transplant. Reported as the cumulative count of participants who received any transplant during the observation period.
Time frame: Up to 4 years
Number of deaths by cause of death category among participants with pulmonary arterial hypertension
Among participants who are deceased, cause of death is recorded using a standardized checklist (right heart failure, sudden cardiac death, cardiogenic shock, malignancy, renal failure, pulmonary hypertension, pulmonary infection, respiratory failure, sepsis/multi-organ failure, transplant-related, unknown, or other). Multiple causes may be selected per decedent; results are reported as the number of deaths attributed to each cause category over the observation period (a single participant may contribute to more than one category).
Time frame: Up to 4 years
Number of pulmonary hypertension-related hospitalizations per participant
Count of inpatient hospitalizations attributed to pulmonary hypertension as documented in the electronic health record. PH-relatedness is determined by the treating clinician and recorded as yes/no. PH-related reasons include right heart failure, cardiogenic shock, worsening pulmonary hypertension, arrhythmia, infection, or transplant. Reported as the number of PH-related hospitalizations per participant.
Time frame: Up to 4 years
Number of pulmonary hypertension-related hospitalizations and observation stays per participant
Count of inpatient hospitalizations and observation stays attributed to pulmonary hypertension as documented in the electronic health record. PH-relatedness is determined by the treating clinician and recorded as yes/no. PH-related reasons include right heart failure, cardiogenic shock, worsening pulmonary hypertension, arrhythmia, infection, or transplant. Reported as the combined number of PH-related inpatient hospitalizations and observation stays per participant.
Time frame: Up to 4 years
Number of emergency department visits per participant
Count of emergency department visits (encounter type = "Emergency Department Visit") as documented in the electronic health record during the observation period. PH-relatedness of each visit is recorded. Reported as the number of ED visits per participant.
Time frame: Up to 4 years
Number of participants receiving each PAH-specific drug therapy regimen (monotherapy, dual, or triple combination) at baseline and at each annual follow-up
PAH-specific medications are recorded by drug class (endothelin receptor antagonist, PDE5 inhibitor, prostacyclin, guanylate cyclase agonist, calcium channel blocker, tyrosine kinase inhibitor, activin pathway inhibitor, or combination pill \[macitentan + tadalafil\]), medication name, dose, frequency, route, start date, and stop date. Treatment regimen intensity is derived from the number of concurrent PAH-specific drug classes prescribed to each participant. Reported as the number of participants on monotherapy (1 class), dual therapy (2 classes), or triple/higher combination therapy (≥3 classes) at baseline and at each annual follow-up.
Time frame: Up to 4 years
Number of participants with each type of clinical management change at each follow-up visit
Clinical management changes are recorded at each visit using a standardized checklist of 22 categories including: hospitalization for PAH/heart failure management, transplant evaluation initiated, listed for transplant, new PAH medication class initiated, prostacyclin therapy titrated, palliative care consultation, and others. Reported as the number of participants with each management change category at each follow-up.
Time frame: Up to 4 years
Number of participants whose treatment changes were primarily driven by each driver category at each follow-up visit
At each visit, the primary driver of treatment changes is recorded from a standardized list of 18 categories including: risk score (PHORA, REVEAL 2.0, REVEAL Lite 2), clinical assessment (gestalt), six-minute walk distance, cardiopulmonary exercise testing, NYHA functional class, echocardiography findings, cardiac MRI findings, natriuretic peptide levels, renal function, hepatic function, other biomarkers, chest X-ray, CT imaging, medication side effects, quality of life assessment, patient or caregiver preference, other, or none. Secondary drivers are also recorded. Reported as the number of participants whose treatment changes were primarily driven by each category at each follow-up.
Time frame: Up to 4 years
Number of participants enrolled at sites that use PAH risk stratification in routine clinical care versus sites that do not
Each participating site reports whether PAH risk stratification is used as part of routine clinical care (yes/no). Reported as the number of participants enrolled at risk-stratification sites compared with the number enrolled at non-risk-stratification sites. This grouping variable enables comparison of clinical outcomes between the two site types.
Time frame: Up to 4 years
PHORA risk score value at each follow-up visit among participants at sites using risk stratification
The PHORA risk score (expressed as a percentage) is recorded from the clinical decision support system at each visit at sites that use PAH risk stratification in routine clinical care. Reported as the mean PHORA risk score (%) at baseline and at each annual follow-up.
Time frame: Up to 4 years
REVEAL 2.0 risk score at each follow-up visit among participants at sites using risk stratification
The REVEAL 2.0 risk score (numeric) is recorded from the clinical decision support system at each visit at sites that use PAH risk stratification in routine clinical care. Reported as the mean REVEAL 2.0 score at baseline and at each annual follow-up.
Time frame: Up to 4 years
REVEAL Lite 2.0 risk score at each follow-up visit among participants at sites using risk stratification
The REVEAL Lite 2.0 risk score (numeric) is recorded from the clinical decision support system at each visit at sites that use PAH risk stratification in routine clinical care. Reported as the mean REVEAL Lite 2.0 score at baseline and at each annual follow-up.
Time frame: Up to 4 years
Plan to share: Undecided — The study team has not yet made a final determination regarding the sharing of individual participant data. Any future data-sharing plans will be evaluated in accordance with applicable privacy regulations, institutional policies, participant consent, and data use agreements.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2031, 48 months later.
Of 64 non-industry observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 31. This study's planned 48 months is below that.
Counting every sponsor, half of 85 studies reached it within 58 months; a quarter within 30 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →
Sentara Norfolk General Hospital